Multiple Myeloma

Two belantamab mafodotin–based combinations have been approved in Japan for relapsed/refractory multiple myeloma.

Elena Maroto-Martin, PhD, discusses the rationale for developing TCR-like CAR T-cell therapy in multiple myeloma and other hematologic malignancies.

Amin Sobh, PhD, discusses ongoing efforts to investigate the role of NSD2 expression in modulating immune surveillance in multiple myeloma.

The allogeneic CAR T-cell therapy CT0596 was safe with clinical activity in relapsed/refractory multiple myeloma.

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.

ISB 2001 has received fast track designation from the FDA for patients with relapsed or refractory multiple myeloma who received 3 or more prior therapies.

The top 5 OncLive videos of the week cover insights in colorectal cancer, prostate cancer, myeloma, renal cell carcinoma, and urothelial carcinoma.

David S. Siegel, MD, explains the rationale for assessing mezigdomide—a novel thalidomide derivative—in relapsed/refractory multiple myeloma.

Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma.

Linvoseltamab earned EC approval for relapsed/refractory multiple myeloma after at least 3 prior lines of therapy.

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

A multicenter review comparing ide-cel and cilta-cel in relapsed/refractory multiple myeloma showed better survival with cilta-cel but increased toxicity.

Janine Joseph, MS, MBA, discusses the current state of research and future directions for resistance training interventions in patients with multiple myeloma.

Kiavasch Mohammad Nejad Farid, MD, discusses 2 planned investigations of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and AL amyloidosis.

Salvage transplant was not associated with long-term survival benefits in relapsed/refractory multiple myeloma.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

María-Victoria Mateos, MD, PhD, discusses data from the long-term update of CARTITUDE-4 she presented during the 51st Annual EBMT Meeting.

Two belantamab mafodotin–based combinations have been approved in the United Kingdom for relapsed/refractory multiple myeloma.

Daratumumab plus lenalidomide maintenance improved clinical outcomes vs lenalidomide monotherapy in multiple myeloma after transplant.

D-VRd has the potential to significantly improve clinical outcomes in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma.

Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.

Daratumumab reduced the risk of disease progression or death vs active monitoring in high-risk smoldering multiple myeloma.

Early infection risk following cilta-cel infusion in patients with multiple myeloma emphasizes the importance of monitoring for treatment-emergent infections.

Alfred L. Garfall, MD, discusses the role of ide-cel in patients with multiple myeloma following suboptimal responses to upfront auto-HCT.

The European Commission approved subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma, regardless of transplant eligibility.